comparemela.com

Latest Breaking News On - Oncocyte corporation - Page 1 : comparemela.com

StockNews.com Begins Coverage on OncoCyte (NASDAQ:OCX)

Analysts at StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Get Free Report) in a research note issued to investors on Thursday. The firm set a “sell” rating on the stock. Several other brokerages have also issued reports on OCX. Stephens reiterated an “equal weight” rating and issued a $4.00 price target on shares […]

United-states
Andrew-arno
Needham-company
Oncocyte-corporation
Securities-exchange-commission
Get-free-report
Broadwood-partners
Exchange-commission
Director-andrew-arno
Cyte-corporation
Oncocyte-daily

Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine

Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Vienna
Wien
Austria
United-states
American
Josh-riggs
Ekke-schuetz
Klemens-budde
Julia-beck
Jeff-ramson
Katharina-mayer
Exchange-commission

Favorable Oncocyte Vitagraft Kidney Study Results Published In The New England Journal Of Medicine

Favorable Oncocyte Vitagraft Kidney Study Results Published In The New England Journal Of Medicine
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

Vienna
Wien
Austria
United-states
American
Jeff-ramson
Georg-bo
Vitagraft-liver
Ekke-schuetz
Klemens-budde
Julia-beck
Josh-riggs

OncoCyte (NASDAQ:OCX) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research note published on Friday. The brokerage issued a sell rating on the stock. Several other brokerages have also recently weighed in on OCX. Needham & Company LLC reiterated a buy rating and issued a $4.25 price objective on shares of OncoCyte […]

United-states
Andrew-arno
Oncocyte-corporation
Needham-company
Securities-exchange-commission
Oncocyte-company-profile
Free-report
Director-andrew-arno
Exchange-commission
Broadwood-partners
Get-free-report
Cyte-corporation

StockNews.com Begins Coverage on OncoCyte (NASDAQ:OCX)

StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research note published on Friday. The brokerage issued a sell rating on the stock. A number of other research firms have also recently commented on OCX. Benchmark restated a speculative buy rating and issued a $5.00 price objective on shares of OncoCyte […]

United-states
Andrew-arno
Oncocyte-corporation
Needham-company
Free-report
Director-andrew-arno
Broadwood-partners
Get-free-report
Cyte-corporation
Oncocyte-daily

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.